Novel subtype of obesity influencing the outcomes of sleeve gastrectomy: Familial aggregation of obesity

Table 3 Preoperative obesity-related comorbidities, n (%)

		n	1SO, n = 80	1FAO, n = 80	χ2	P value	n	2SO, n = 58	2FAO, n = 58	χ2	P value
MS	Without	89	43 (53.8)	46 (57.5)	0.228	0.633	67	34 (58.6)	33 (56.9)	0.035	0.851
	With	71	37 (46.3)	34 (42.5)			49	24 (41.4)	25 (43.1)
HTN	Without	105	54 (67.5)	51 (63.8)	0.249	0.618	75	33 (56.9)	42 (72.4)	3.056	0.080
	With	55	26 (32.5)	29 (36.3)			41	25 (43.1)	16 (27.6)
T2DM	Without	86	43 (53.8)	43 (53.8)		> 0.999	59	31 (53.4)	28 (48.3)	0.310	0.577
	With	74	37 (46.3)	37 (46.3)			57	27 (46.6)	30 (51.7)
IGT	Without	89	45 (56.3)	44 (55.0)	0.025	0.874	71	33 (56.9)	38 (65.5)	0.908	0.341
	With	71	35 (43.8)	36 (45.0)			45	25 (43.1)	20 (34.5)
HLP	Without	96	51 (63.8)	45 (56.3)	0.938	0.333	68	39 (67.2)	29 (50.0)	3.554	0.059
	With	64	29 (36.3)	35 (43.8)			48	19 (32.8)	29 (50.0)
PCOS	Without	87	41 (74.5)	46 (80.7)	0.612	0.434	52	27 (77.1)	25 (73.5)	0.157	0.924
	With	25	14 (25.5)	11 (19.3)			17	8 (22.9)	9 (26.5)
NAFLD	Without	26	16 (20.0)	10 (12.5)	1.653	0.199	19	8 (13.8)	11 (19.0)	0.566	0.452
	With	134	64 (80.0)	70 (87.5)			97	50 (86.2)	47 (81.0)
OSA	Without	53	27 (33.8)	26 (32.5)	0.028	0.867	37	14 (24.1)	23 (39.7)	3.215	0.073
	With	107	53 (66.3)	54 (67.5)			79	44 (75.9)	35 (60.3)
HUA	Without	68	37 (46.3)	31 (38.8)	0.921	0.337	42	18 (31.0)	24 (41.4)	1.344	0.246
	With	92	43 (53.8)	49 (61.3)			74	40 (69.0)	34 (58.6)

Only female participants were analyzed to compare polycystic ovarian syndrome prevalence. The number of females is 112 [¹sporadic obesity (SO) vs¹familial aggregation of obesity (FAO) = 55 vs 57] and 69 (²SO vs²FAO = 35 vs 34). SO: Sporadic obesity; FAO: Familial aggregation of obesity; MS: Metabolic syndrome; HTN: Hypertension; T2DM: Type 2 diabetes mellitus; IGT: Impaired glucose tolerance; HLP: Hyperlipoidemia; PCOS: Polycystic ovarian syndrome; NAFLD: Non-alcoholic fatty liver disease; OSA: Obstructive sleep apnea; HUA: Hyperuricemia.